Embecta Corp. to Acquire Owen Mumford for up to £150M, Expanding Drug-Delivery Portfolio

summarizeSummary

Embecta Corp. announced a definitive agreement to acquire Owen Mumford Holdings Limited for up to £150 million, a strategic move to expand its drug-delivery device portfolio and accelerate its transformation into a broad-based medical supplies company.

check_boxKey Events

• Definitive Acquisition Agreement

  Embecta Corp. has entered into a definitive agreement to acquire Owen Mumford Holdings Limited, a UK-based medical device and drug-delivery technology company.

• Transaction Value

  The acquisition is valued at up to £150 million, consisting of an upfront cash payment of £100 million and up to £50 million in performance-based earn-out payments.

• Strategic Expansion

  The acquisition is expected to accelerate Embecta's transformation into a broad-based medical supplies company, adding a differentiated drug-delivery platform and expanding its chronic care device portfolio.

• Financial Impact

  The transaction is anticipated to be dilutive to adjusted net income in fiscal year 2027, becoming immaterial in fiscal year 2028, and accretive thereafter, with high-single-digit return on invested capital by year four.

auto_awesomeAnalysis

Embecta Corp. has entered into a definitive agreement to acquire Owen Mumford Holdings Limited, a UK-based medical device and drug-delivery technology innovator. The transaction is valued at up to £150 million, comprising an upfront cash payment of £100 million and up to an additional £50 million in performance-based payments tied to net sales of the Aidaptus auto-injector platform over three years. This acquisition is a significant strategic move for Embecta, aiming to transform it into a broad-based medical supplies company and improve its revenue growth trajectory. While the deal is expected to be dilutive to adjusted net income in fiscal year 2027, it is projected to become accretive thereafter and generate high-single-digit return on invested capital by year four. The upfront payment will be financed through borrowings under Embecta's revolving credit facility.